Daklinza (daclatasvir) is an HCV-fighting drug that blocks different steps of the virus life cycle. In the United States, Daklinza is approved for people over 18 years old who have HCV genotype 1 or genotype 3 (although it has been used in other genotypes).
Ribavirin (RBV) is an HCV-fighting drug. RBV does not work by itself. Adding RBV to other drugs can increase the chance of being cured from HCV. In the United States, ribavirin is approved for children (3 to 18 years of age) and adults.
What is adherence? Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C…
Olysio (simeprevir) is an HCV-fighting drug. It must be used with other drugs to treat hepatitis C. In the United States, Olysio is approved for people with hepatitis C genotype 1 who are over 18 years old.
This brief review provides community recommendations for research that requires HIV-positive people to interrupt antiretroviral treatment (ART).
July 2014 Examples of media coverage: HIV “Cleared” in Two Australian Men after Bone-Marrow Transplants– Sydney Morning Herald, July 19, 2014 HIV Said Cleared in Two Bone Marrow Transplant Patients– Bloomberg News, July 18, 2014 Cancer Treatment Clears Two Australian Patients…
TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.
February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis…